Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis ; volume:26 ; number:1 ; day:6 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
Breast cancer research ; 26, Heft 1 (6.11.2024), 1-10, 12.2024
- Creator
-
Kook, Yoonwon
Lee, Young-jin
Chu, Chihhao
Jang, Ji Soo
Baek, Seung Ho
Bae, Soong June
Cha, Yoon Jin
Gong, Gyungyup
Jeong, Joon
Lee, Sae Byul
Ahn, Sung Gwe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-024-01911-9
- URN
-
urn:nbn:de:101:1-2502112157024.408813196296
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kook, Yoonwon
- Lee, Young-jin
- Chu, Chihhao
- Jang, Ji Soo
- Baek, Seung Ho
- Bae, Soong June
- Cha, Yoon Jin
- Gong, Gyungyup
- Jeong, Joon
- Lee, Sae Byul
- Ahn, Sung Gwe
- SpringerLink (Online service)
Other Objects (12)
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom